Top

Published in:

01-12-2008

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children

Authors: M. Sue O’Dorisio, Geetika Khanna, David Bushnell

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Abstract

Combining anatomical and functional imaging can improve sensitivity and accuracy of tumor diagnosis and surveillance of pediatric malignancies. MRI is the state-of-the-art modality for demonstrating the anatomical location of brain tumors with contrast enhancement adding additional information regarding whether the tumor is neuronal or glial. Addition of SPECT imaging using a peptide that targets the somatostatin receptor (Octreoscan) can now differentiate medulloblastoma from a cerebellar pilocytic astrocytoma. Combined MRI and Octreoscan is now the most sensitive and accurate imaging modality for differentiating recurrent medulloblastoma from scar tissue. CT is the most common imaging modality for demonstrating the anatomical location of tumors in the chest and abdomen. Addition of SPECT imaging with either MIBG or Octreoscan has been shown to add important diagnostic information on the nature of tumors in chest and abdomen and is often more sensitive than CT for identification of metastatic lesions in bone or liver. Combined anatomical and functional imaging is particularly helpful in neuroblastoma and in neuroendocrine tumors such as gastrinoma and carcinoid. Functional imaging with MIBG and Octreoscan is predictive of response to molecularly targeted therapy with 131I-MIBG and 90Y-DOTA-tyr3-Octreotide. Dosimetry using combined anatomical and functional imaging is being developed for patient-specific dosing of targeted radiotherapy and as an extremely sensitive monitor of response to therapy. Both MIBG and Octreotide are now being adapted to PET imaging which will greatly improve the utility of PET in medulloblastoma as well as increase the sensitivity for detection of metastatic lesions in neuroblastoma and neuroendocrine tumors.

Heideman, R. L., Packer, R. J., Albright, L. A., Freeman, C. R., & Rorke, L. B. (1997). In P. A. Pizzo, & D. G. Poplack (Eds.), Principles and practice of pediatric oncology pp. 633–697. Philadelphia: Lippincott-Raven.

Hirakawa, K., Suzuki, K., Ueda, S., & Handa, J. (1986). Fetal origin of the medulloblastoma: Evidence from growth analysis of two cases. Acta Neuropathologica (Berl), 70(3–4), 227–234.CrossRef

Yachnis, A. T., Rorke, L. B., & Trojanowski, J. Q. (1994). Cerebellar dysplasias in humans: Development and possible relationship to glial and primitive neuroectodermal tumors of the cerebellar vermis. Journal of Neuropathology and Experimental Neurology, 53(1), 61–71.PubMedCrossRef

Scherini, E., & Bernocchi, G. (1994). CisDDP treatment and development of the rat cerebellum. Progress in Neurobiology, 42(2), 161–196.PubMedCrossRef

Zhang, L., & Goldman, J. E. (1996). Generation of cerebellar interneurons from dividing progenitors in white matter. Neuron, 16(1), 47–54.PubMedCrossRef

Rubinstein, L. J. (1985). Embryonal central neuroepithelial tumors and their differentiating potential. A cytogenetic view of a complex neuro-oncological problem. Journal of Neurosurgery, 62(6), 795–805.PubMed

Bailey, P., & Cushing, H. (1925). Medulloblastoma cerebelli: A common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.

Trojanowski, J. Q., Tohyama, T., & Lee, V. M. (1992). Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. Molecular and Chemical Neuropathology, 17(2), 121–135.PubMed

Packer, R. J. (1999). Childhood medulloblastoma: Progress and future challenges. Brain & Development, 21(2), 75–81.CrossRef

10.

Gurney, J. G., Kadan-Lottick, N. S., Packer, R. J., Neglia, J. P., Sklar, C. A., Punyko, J. A., et al. (2003). Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer, 97(3), 663–673.PubMedCrossRef

11.

Fangusaro, J., Finlay, J., Sposto, R., Ji, L., Saly, M., Zacharoulis, S., et al. (2007). Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatr Blood Cancer.

12.

Bull, K. S., Spoudeas, H. A., Yadegarfar, G., & Kennedy, C. R. (2007). Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: A follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). Journal of Clinical Oncology, 25(27), 4239–4245.PubMedCrossRef

13.

Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol, 4(5), 295–304.PubMedCrossRef

14.

Dennis, M., Spiegler, B. J., Hetherington, C. R., & Greenberg, M. L. (1996). Neuropsychological sequelae of the treatment of children with medulloblastoma. Journal of Neuro-oncology, 29(1), 91–101.PubMedCrossRef

15.

Hoppe-Hirsch, E., Brunet, L., Laroussinie, F., Cinalli, G., Pierre-Kahn, A., Renier, D., et al. (1995). Intellectual outcome in children with malignant tumors of the posterior fossa: Influence of the field of irradiation and quality of surgery. Child’s Nervous System, 11(6), 340–345.PubMedCrossRef

16.

David, K. M., Casey, A. T., Hayward, R. D., Harkness, W. F., Phipps, K., & Wade, A. M. (1997). Medulloblastoma: Is the 5-year survival rate improving? A review of 80 cases from a single institution. Journal of Neurosurgery, 86(1), 13–21.PubMed

17.

Khanna, G., O’Dorisio, M. S., Menda, Y., Glasier, C., Deyoung, B., Smith, B. J., et al. (2007). Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatric Blood and Cancer, 50, 561–566.CrossRef

18.

Biegel, J. A. (1997). Genetics of pediatric central nervous system tumors. Journal of Pediatric Hematology Oncology, 19(6), 492–501.CrossRef

19.

Wilgenbus, K. K., Seranski, P., Brown, A., Leuchs, B., Mincheva, A., Lichter, P., et al. (1997). Molecular characterization of a genetically unstable region containing the SMS critical area and a breakpoint cluster for human PNETs. Genomics, 42(1), 1–10.PubMedCrossRef

20.

Bigner, S. H., & Schrock, E. (1997). Molecular cytogenetics of brain tumors. Journal of Neuropathology and Experimental Neurology, 56(11), 1173–1181.PubMedCrossRef

21.

MacGregor, D. N., & Ziff, E. B. (1990). Elevated c-myc expression in childhood medulloblastomas. Pediatric Research, 28(1), 63–68 Ref Type: Abstract.PubMedCrossRef

22.

Fruhwald, M. C., O’Dorisio, M. S., Rush, L. J., Reiter, J. L., Smiraglia, D. J., Wenger, G., et al. (2000). Gene amplification in PNETs/medulloblastomas: Mapping of a novel amplified gene within the MYCN amplicon. Journal of Medical Genetics, 37(7), 501–509.PubMedCrossRef

23.

Goodrich, L. V., Milenkovic, L., Higgins, K. M., & Scott, M. P. (1997). Altered neural cell fates and medulloblastoma in mouse patched mutants. Science, 277(5329), 1109–1113.PubMedCrossRef

24.

Pietsch, T., Waha, A., Koch, A., Kraus, J., Albrecht, S., Tonn, J., et al. (1997). Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Research, 57(11), 2085–2088.PubMed

25.

Zakrzewska, M., Rieske, P., biec-Rychter, M., Zakrzewski, K., Polis, L., Fiks, T., et al. (2004). Molecular abnormalities in pediatric embryonal brain tumors-analysis of loss of heterozygosity on chromosomes 1, 5, 9, 10, 11, 16, 17 and 22. Clinical Neuropathology, 23(5), 209–217.PubMed

26.

Wolter, M., Reifenberger, J., Sommer, C., Ruzicka, T., & Reifenberger, G. (1997). Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Research, 57(13), 2581–2585.PubMed

27.

Uziel, T., Zindy, F., Xie, S., Lee, Y., Forget, A., Magdaleno, S., et al. (2005). The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes & Development, 19(22), 2656–2667.CrossRef

28.

Zindy, F., Uziel, T., Ayrault, O., Calabrese, C., Valentine, M., Rehg, J. E., et al. (2007). Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Research, 67(6), 2676–2684.PubMedCrossRef

29.

Muhlisch, J., Bajanowski, T., Rickert, C. H., Roggendorf, W., Wurthwein, G., Jurgens, H., et al. (2007). Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. Journal of Neuro-oncology, 83(1), 17–29.PubMedCrossRef

30.

Sardi, I., Cavalieri, D., & Massimino, M. (2007). Emerging treatments and gene expression profiling in high-risk medulloblastoma. Paediatric Drugs, 9(2), 81–96.PubMedCrossRef

31.

Brodeur, G. M., & Maris, J. M. (2001). In P. A. Pizzo, & D. G. Poplack (Eds.), Principles and practice of pediatric oncology pp. 895–937. Philadelphia: Lippincott Williams & Wilkins.

32.

Thiele, C. J. (1991). Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Reviews, 10(4), 311–319.PubMedCrossRef

33.

Dehner, L. P. (1993). Primitive neuroectodermal tumor and Ewing’s sarcoma. American Journal of Surgical Pathology, 17(1), 1–13.PubMedCrossRef

34.

Kitlinska, J., Abe, K., Kuo, L., Pons, J., Yu, M., Li, L., et al. (2005). Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Research, 65(5), 1719–1728.PubMedCrossRef

35.

Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. New England Journal of Medicine, 341(16), 1165–1173.PubMedCrossRef

36.

Altungoz, O., Aygun, N., Tumer, S., Ozer, E., Olgun, N., & Sakizli, M. (2007). Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. Cancer Genetics and Cytogenetics, 172(2), 113–119.PubMedCrossRef

37.

Gurcan, M. N., Pan, T., Shimada, H., & Saltz, J. (2006). Image analysis for neuroblastoma classification: Segmentation of cell nuclei. Conference Proceedings of IEEE Engineering in Medicine and Biology Society, 1, 4844–4847.CrossRef

38.

Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224(4653), 1121–1124.PubMedCrossRef

39.

Sano, H., Bonadio, J., Gerbing, R. B., London, W. B., Matthay, K. K., Lukens, J. N., et al. (2006). International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. European Journal of Cancer, 42(8), 1113–1119.PubMedCrossRef

40.

Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., Eick, G. N., Mane, S. M., et al. (2006). Genetic differentiation of appendiceal tumor malignancy: A guide for the perplexed. Annals of Surgery, 244(1), 52–60.PubMedCrossRef

41.

Stinner, B., & Rothmund, M. (2005). Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol, 19(5), 729–738.PubMedCrossRef

42.

Khanna, G., O’Dorisio, M. S., Menda, Y., Kirby, P., Kao, S., & Sato, Y. (2007). Gastroenteropancreatic Neuroendocrine Tumors in Children and Young Adults. Pediatric Radiology, 38, 251–259.PubMedCrossRef

43.

SEER Cancer Statistics Review, 1973–2004. 1-11-2006. Ref Type: Report

44.

Vinik, A. I., Thompson, N., Eckhauser, F., & Moattari, A. R. (1989). Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncologica, 28(3), 389–402.PubMedCrossRef

45.

Lamberts, S. W., Pieters, G. F., Metselaar, H. J., Ong, G. L., Tan, H. S., & Reubi, J. C. (1988). Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinologica (Copenh), 119(4), 561–566.

46.

McDermott, E. W., Guduric, B., & Brennan, M. F. (1994). Prognostic variables in patients with gastrointestinal carcinoid tumours. British Journal of Surgery, 81(7), 1007–1009.PubMedCrossRef

47.

Broaddus, R. R., Herzog, C. E., & Hicks, M. J. (2003). Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Archives of Pathology and Laboratory Medicine, 127(9), 1200–1203.PubMed

48.

Pashankar, F. D., O’Dorisio, M. S., & Menda, Y. (2005). MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. Journal of Nuclear Medicine, 46(Suppl 1), 55S–61S.PubMed

49.

Kloppel, G. PAHP. (2004). The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Annals of the New York Academy of Sciences, 1014, 13–27 Ref Type: Generic.PubMedCrossRef

50.

Rindi, G., Kloppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., et al. (2006). TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Archives, 449(4), 395–401.CrossRef

51.

Modlin, I. M., Lye, K. D., & Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4), 934–959.PubMedCrossRef

52.

Bonato, M., Cerati, M., Pagani, A., Papotti, M., Bosi, F., Bussolati, G., et al. (1992). Differential diagnostic patterns of lung neuroendocrine tumours. A clinico-pathological and immunohistochemical study of 122 cases. Virchows Archiv. A, Pathological Anatomy and Histopathology, 420(3), 201–211.PubMedCrossRef

53.

Modlin, I. M., Kidd, M., Pfragner, R., Eick, G. N., & Champaneria, M. C. (2006). The functional characterization of normal and neoplastic human enterochromaffin cells. Journal of Clinical Endocrinology and Metabolism, 91(6), 2340–2348.PubMedCrossRef

54.

Kulke, M. H., & Mayer, R. J. (1999). Carcinoid tumors. New England Journal of Medicine, 340(11), 858–868.PubMedCrossRef

55.

Rindi, G., Capella, C., Bordi, C., & Solcia, E. (2002). Guidelines and minimal diagnostic criteria for the histological diagnosis of endocrine tumors of the gastroenteropancreatic type. Pathologica, 94(3), 142–147.PubMed

56.

Fiocca, R., Rindi, G., Capella, C., Grimelius, L., Polak, J. M., Schwartz, T. W., et al. (1987). Glucagon, glicentin, proglucagon, PYY, PP and proPP-icosapeptide immunoreactivities of rectal carcinoid tumors and related non-tumor cells. Regulatory Peptide, 17(1), 9–29.CrossRef

57.

Shankar, L. K., Hoffman, J. M., Bacharach, S., Graham, M. M., Karp, J., Lammertsma, A. A., et al. (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of Nuclear Medicine, 47(6), 1059–1066.PubMed

58.

Ott, R. J., Tait, D., Flower, M. A., Babich, J. W., & Lambrecht, R. M. (1992). Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. British Journal of Radiology, 65(777), 787–791.PubMed

59.

Maecke, H. R., Hofmann, M., & Haberkorn, U. (2005). (68)Ga-labeled peptides in tumor imaging. Journal of Nuclear Medicine, 46(Suppl 1), 172S–178S.PubMed

60.

Nataf, V., Balard, M., de B, V., Kerrou, K., Gutman, F., Grahek, D., et al. (2006). Safety of 18F-DOPA Injection for PET of Carcinoid Tumor. Journal of Nuclear Medicine, 47(10), 1732.PubMed

61.

Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., et al. (2005). Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Journal of Clinical Oncology, 23(21), 4652–4661.PubMedCrossRef

62.

Howard, J. P., Maris, J. M., Kersun, L. S., Huberty, J. P., Cheng, S. C., Hawkins, R. A., et al. (2005). Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatric Blood and Cancer, 44(3), 232–239.PubMedCrossRef

63.

Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., et al. (2003). High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer, 98(2), 239–248.PubMedCrossRef

Title: Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children
Authors: M. Sue O’Dorisio
Geetika Khanna
David Bushnell
Publication date: 01-12-2008
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9153-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Imaging hemodynamics

Imaging matrix metalloproteinases in cancer

The role of DNA synthesis imaging in cancer in the era of targeted therapeutics

Imaging of integrin αvβ3 expression

Caveolin-1 in tumor progression: the good, the bad and the ugly

Tumor detection using folate receptor-targeted imaging agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer